More specifically, the anti-CD20 antibodies rituximab, ofatumumab and obinutuzumab have been associated with reactivation of hepatitis B and rarely, progressive multifocal leukoencephalopathy. The gene discussed is MS4A1; the disease is progressive multifocal leukoencephalopathy.